Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
| Autor: | Ines Bilić Ćurčić, Aleksandar Včev, Nikola Raguž Lučić, Martina Smolić, Kristina Bojanic, Robert Smolić, Vatroslav Šerić, Tomislav Kizivat, Lucija Kuna, Sandra Tucak-Zorić, Kristina Kralik, Gordana Ivanac |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Bone density Anastrozole lcsh:Medicine 030209 endocrinology & metabolism Article aromatase inhibitors Wnt signaling pathway 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Internal medicine medicine breast neoplasms Aromatase bone density Femoral neck Bone mineral biology business.industry lcsh:R General Medicine medicine.disease Endocrinology medicine.anatomical_structure chemistry DKK1 030220 oncology & carcinogenesis biology.protein Sclerostin business medicine.drug |
| Zdroj: | Journal of Clinical Medicine, Vol 7, Iss 9, p 287 (2018) Journal of Clinical Medicine; Volume 7; Issue 9; Pages: 287 Journal of Clinical Medicine |
| DOI: | 10.3390/jcm7090287. |
| Popis: | Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters. Methods: 137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual-energy X-ray absorptiometry (DXA). Lifestyle factors were investigated by a self-reported questionnaire. Results: Sclerostin was significantly higher in the AI-treated group (31.8 pmol/L vs. 24.1 pmol/L; p < 0.001), whereas DKK1 was significantly lower in the AI-treated group (24.3 pmol/L vs. 26.02 pmol/L; p < 0.001). Total hip and femoral neck BMD were significantly lower in the AI-treated group. Conclusion: AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|